Recap: Vericel Q3 Earnings
Vericel (NASDAQ:VCEL) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
SVB Leerink Maintains Outperform on Vericel, Lowers Price Target to $62
SVB Leerink analyst Danielle Antalffy maintains Vericel (NASDAQ:VCEL) with a Outperform and lowers the price target from $67 to $62.
Vericel Q2 EPS $(0.08), Inline, Sales $39.52M Beat $36.67M Estimate
Vericel (NASDAQ:VCEL) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 55.56 percent increase over losses of $(0.18) per share from the same period last year. The
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Understanding Vericel’s Unusual Options Activity
Vericel (NASDAQ:VCEL) shares experienced unusual options activity on Tuesday. The stock price moved down to $52.56 following the option alert.